A multicentre outcome research in daily clinical practice concerning the prevention of acute and delayed nausea and vomiting after chemotherapy: an outcome research.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON27981

Enrollment

600

Registered

2007-06-19

Start date

2005-04-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chemotherapy induced nausea and vomiting, adherence to guidelines, efficacy antiemetics, quality of life. chemotherapie geinduceerde misselijkheid en braken, opvolgen behandelrichtlijnen, effectiviteit anti-emetica, kwaliteit van leven

Interventions

This study uses self reported sides effects including nausea and vomiting by means of a patient diary which also includes a quality of life assessment.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Chemotherapy naive patients receiving chemotherapy.

Exclusion criteria

Exclusion criteria: 1. Life expectancy less than three months; 2. Lack of basic proficiency in Dutch; 3. Age below 18; 4. Pregnancy; 5. Psychological illness.

Design outcomes

Primary

Measure	Time frame
1. To make an inventory on the antiemetic policy in several peripheral hospitals; 2. To make an inventory on the effectiveness of these antiemetic policies.	—

Secondary

Measure	Time frame
1. What is the difference in antiemetic policies used in several peripheral hospitals? 2. Do these antiemetic policies correspond with evidence based guidelines? 3. Is aprepitant used in high emetogenic chemotherapy treatment or moderate emetogenic chemotherapy treatment? 4. What is the incidence of acute and delayed nausea and vomiting in chemotherapy treatment and does this correspond with literature? 5. Can differences in effectiveness be explained by differences in patient characteristics, chemotherapy and/or antiemetic policy?	—

Measure

Time frame

1. What is the difference in antiemetic policies used in several peripheral hospitals? 2. Do these antiemetic policies correspond with evidence based guidelines? 3. Is aprepitant used in high emetogenic chemotherapy treatment or moderate emetogenic chemotherapy treatment? 4. What is the incidence of acute and delayed nausea and vomiting in chemotherapy treatment and does this correspond with literature? 5. Can differences in effectiveness be explained by differences in patient characteristics, chemotherapy and/or antiemetic policy?

—

Contacts

Public ContactH.J. Doodeman

Medical Centre Alkmaar, Hospital Pharmacy P.O. Box 501

h.j.doodeman@mca.nl+31 72-5483591

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)